Drug Type Small molecule drug |
Synonyms Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane, GB0 139, GB0-139 + [1] |
Target |
Action inhibitors |
Mechanism galectin-3 inhibitors(Galectin-3 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC28H30F2N6O8S |
InChIKeyYGIDGBAHDZEYMT-MQFIMZJJSA-N |
CAS Registry1450824-22-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 2 | United Kingdom | 13 Jun 2020 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | United States | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Australia | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Belgium | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Canada | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | France | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Georgia | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Germany | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Ireland | 19 Feb 2019 | |
Idiopathic Pulmonary Fibrosis | Phase 2 | Israel | 19 Feb 2019 |
Phase 2 | 172 | (A. GB0139 3 mg Once a Day) | bbpoybrnxp(xeenxgwyvp) = qtxeqqjctt bydujdycos (vpposdbxoa, yqohlufpso - isxoqkulrq) View more | - | 22 May 2024 | ||
Placebo (B. Placebo Once a Day) | bbpoybrnxp(xeenxgwyvp) = ukauloqawi bydujdycos (vpposdbxoa, fnbjkjcmzg - yboincvfds) View more | ||||||
Phase 1/2 | 41 | Standard of Care+GB0139 | arslogkeja(iudpdynusn) = ehijryupjl koovnhssbj (nbzroxuhaq ) View more | Positive | 22 Jun 2021 | ||
Standard of Care | - | ||||||
Phase 1 | - | ujnpjmeiap(pyhhdiulsg) = yrkmyklgzw ztbcftdewk (zrnhsrajxx ) View more | - | 01 May 2021 |